To include your compound in the COVID-19 Resource Center, submit it here.

ImmunoGen reports Phase I data for IMGN779 in AML

ImmunoGen Inc. (NASDAQ:IMGN) reported data from the dose-escalation portion of an open-label, U.S. Phase I trial in patients with relapsed or

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE